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How Valuable as a Diagnostic and Therapeutic Tool?*Stanley S. Franklin, MD, Nathan D. Wong, PHDSEE PAGE 392C ross-sectional and longitudinal studies ofage-related increases in blood pressure (BP)have shown that mean diastolic blood pres-
sure (DBP) levels off by approximately age 50 years
and begins to decrease by age 60 years, whereas sys-
tolic blood pressure (SBP) continues to increase; this
results in a slow widening of pulse pressure (PP)
between the ages of 50 years and 60 years and more
rapid widening thereafter as the decrease in DBP
accelerates with more vascular aging (1,2). Elevated
mean artery pressure (MAP), as a measure of steady-
state resistance, is the dominant factor in the almost
parallel increase in SBP and DBP during early adult-
hood; whereas widening PP as a marker of large artery
stiffness is the dominant pulsatile force that contrib-
utes to vascular aging from middle age onward.
Indeed, by middle age, isolated systolic hypertension
(ISH) becomes the dominant form of hypertension (3).
However, at any given SBP, the decrease in DBP adds
to the risk of SBP (4). The potential clinical value of
the widening of PP as a cardiovascular disease (CVD)
factor was ﬁrst suggested in a seminal publication
by Darne et al. (5) in 1989. Since then, the Framing-
ham Heart Study and others (6,7), using the combina-
tion of MAP and PP together, rather than any single
BP component separately (SBP, DBP, MAP, or PP)
improved the ﬁt monotonically for predicting CVD
collectively or coronary heart disease, heart failure,
and stroke separately (7,8). Using the 7th Report of
the Joint National Committee for CVD risk classiﬁca-
tion, a DBP <70 mm Hg can add w20 mm Hg of SBP*Editorials published in the Journal of the American College of Cardiology
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and from stage 1 to stage 2 hypertension) (7). During
the past 20 years, there have been multiple observa-
tional studies and controlled trials showing the value
of PP as an important risk factor for CVD and as a
measure of early vascular aging. Moreover, the Euro-
pean Society of Hypertension has recognized
widened PP as a distinct risk factor that is separate
from elevated SBP in older individuals (9).It is with this background that the authors, using
data from the Reduction of Atherothrombosis for
Continued Health (REACH) registry examined the
relationship between PP and adverse CVD events (10),
published in this issue of the Journal. The novelty of
the REACH registry is that it is the largest inter-
national patient population to study PP,which enabled
the authors to adjust for a signiﬁcant number of
potential confounding factors, and to be able to
perform several key subgroup analyses with substan-
tial statistical power. The study consisted of >45,000
individuals (mean age: 68 years) from 45 countries
who had clinical atherothrombotic disease or baseline
CVD risk factors and subsequently had a 4-year follow-
up for new CVD events. Eighty-one percent were
receiving antihypertensive therapy. Univariable and
multivariable regression analyses were used to deter-
mine the association between PP and CVD outcomes as
continuous and categorical variables (i.e., by quartile
with Forest plots). Not unexpectedly, a higher PP
conferred increased risk for multiple CVD events
although the increases in risk were modest at best.
Furthermore, PP in subgroups of women, persons free
of clinical CVD, and in treatment-naïve individuals,
continued to predict increased CVD risk.
Sensitivity analyses showed: 1) PP was of strong
prognostic value in the absence of prior CVD events; 2)
PP was particularly useful in participants >60 years of
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405age; 3) the degree of systolic hypertension was associ-
ated with increased risk for nonfatal myocardial
infarctions and combined outcomes; and 4) antihy-
pertensive treatment was associated with greater risk
of hospitalization, myocardial infarctions, and com-
bined events. In summary, the REACH registry authors
concluded that PP was associated with multiple CVD
outcomes that provided prognostic utility beyond that
of MAP. On the other hand, this study should be
interpreted within the context of its limitations.
ERRORS OF DIAGNOSIS
The authors note that there was zero-digit preference
bias in 58% for SBP and 60% for DBP, when the
expected number was 20%. This highlights the almost
universal poor technique of BP measurement by
physicians and nurses in an ofﬁce setting that result
in errors in calculating PP accurately. Importantly, in
a recent International Database on Ambulatory Blood
Pressure Monitoring (ABPM) in Relation to Cardio-
vascular Outcomes study of older persons (mean age:
74 years) with ISH, there was a 73% inaccurate diag-
nosis by exclusive use of conventional clinic or ofﬁce
BP measurements; failure to diagnose white-coat
hypertension falsely widened PP, whereas failure to
correctly diagnose masked hypertension falsely con-
tracted PP (11).
Indeed, as the authors of the REACH registry
noted, ABPM with measurement of daytime, night-
time, and 24-h measurements is the gold standard
for accurate diagnosis of all BP components. Howev-
er, a less expensive fully automated ofﬁce device,
which takes multiple readings with subjects resting
quietly alone results in improved measurement of all
BP components including PP (12). Thus, such
misclassiﬁcation, while not unique to REACH, can
result in observed effects on PP that may be less than
what may be present with greater accuracy in mea-
surement. In addition, the high prevalence of treat-
ment in the REACH population suggests that widened
PP may have been more prevalent in the absence of
treatment, given the greater SBP lowering effect
(relative to DBP lowering) from antihypertensive
treatment. The relatively modest hazard ratios (even
those in the 4th quartile of PP) may be due to the
older age of the cohort, the many comorbidities, and/
or being on antihypertensive treatment. The J-shaped
curve of PP with CVD mortality is also not surprising
and probably represents reversed causality.
ERRORS OF TREATMENT
Considering PP in isolation can result in errors of
treatment. For example, a PP of 75 mmHg correspondsto either a BP of 165/90 mm Hg with an elevated
MAP of 115 mm Hg or 140/65 mm Hg with a MAP of
90 mm Hg. Focusing on PP alone does not clarify
which physiologic component of elevated BP is
contributing to CVD risk, and therefore what approach
should be taken to reduce risk, (i.e., treatment may be
directed at reducing MAP in the ﬁrst person and
reducing arterial stiffness in the second person with
minimal further reduction in MAP). Moreover, there is
evidence of a DBP J-curve of increased CVD risk in
individuals with ISH and DBP <70 mm Hg, which
occurred inw30% of untreated older persons with ISH
in the National Health and Nutrition Examination
Survey (13). There was a 3-fold greater prevalence of
CVD events from the highest to the lowest strata in
untreated ISH. Advanced age, female sex, and dia-
betes mellitus, but not treatment status was associ-
ated with the low DBP and widened PP. Lastly, the
elderly hypertensive person with ISH and widened PP,
with or without excessively low DBP, should be clas-
siﬁed as being either robust or frail. Indeed, ABPM
may detect de novo orthostatic hypotension and/or
precipitated by post-prandial and/or post-micturition
states; thus, various degrees of frailty would dictate
the limits of treatment in persons with ISH and
widened PP. Importantly, although elevated PP pro-
vides useful prognostic information, the ultimate goal
of therapy is dictated by how low to go in reducing
SBP. The recently published SPRINT (Systolic Blood
Pressure Intervention Trial), utilizing an automated
BP measuring device, will undoubtedly have a bearing
on the establishing of new SBP but not PP guidelines
for the treatment of hypertension (14). Therefore, the
relationship of PP with CVD risk should always be
examined in the context of (e.g., stratiﬁed by) levels of
SBP and ideally in a more treatment-naïve population.
In summary, as shown in the REACH registry
study, a widened PP can be a reliable prognostic
indicator of CVD risk and the authors are to be
applauded for conducting a thorough and compre-
hensive analysis of this issue. However, a widened
PP represents a “double-edged sword” in terms of
potential pitfalls in making diagnostic and thera-
peutic decisions. In future hypertension guideline
development there should be continued discussion
of the potential role of PP in further risk stratiﬁca-
tion beyond traditional staging based on SBP and
DBP.
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